As selleck chem FTY720 described in more detail below, the study is collecting longitudinal data from approximately 1380 patients from 18 different primary care practices, most of which are not affiliated with an academic institution, and which range greatly in size and proximity to urban centers. The sociodemographic characteristics of the patient populations served by these practices also

vary, including several populations that are more than 50% racial or ethnic minorities. The study Inhibitors,research,lifescience,medical selects from each practice a representative sample of older patients, including an oversample of the very old, from which patients with mild-tosevere depression are identified, recruited, and followed prospectively. Aims The primary aims of PROSPECT are to test the following in a representative sample of older patients in primary care practices: The Inhibitors,research,lifescience,medical effectiveness of its proposed intervention in preventing and reducing suicidal ideation, hopelessness, and depression. The impact of the intervention on the initiation of treatment and outcomes (depression,

disability, Inhibitors,research,lifescience,medical medical morbidity, cognitive dysfunction) in those patients whose characteristics place them at high risk for suicide. The effectiveness of the intervention in preventing and reducing sequelae or complications of depression associated with suicidal behavior, including substance abuse, sleep disturbances, pain, and http://www.selleckchem.com/products/lapatinib.html disability Inhibitors,research,lifescience,medical in elderly patients with degressive signs and symptoms. PROSPECTS intervention

PROSPECT’S “guideline management” intervention implements procedures in primary care practices designed to facilitate the use of a comprehensive treatment algorithm for Inhibitors,research,lifescience,medical depression based on the Agency for Health Care Policy and Research (AHCPR) guidelines. In designing the intervention, the investigators drew not only from their clinical research, but also from the intervention studies for depression in mixed-aged or older primary care patients as well as studies of other chronic conditions of late life. The resulting intervention reflects several current trends in primary Drug_discovery care practice: (i) using practice guidelines and/ or critical pathways to guide treatment decisions; (ii) adding physician extenders for disease-specific case management (such as an anticoagulation nurse-specialist or diabetes nurse); and (iii) strengthening patient compliance with treatment regimens through patient and family education strategics. These components and their rationale are described in the following paragraphs. PROSPECT’S intervention begins with an algorithm for treating late-life depression in primary care settings through the acute, continuation, and maintenance phases. The algorithm draws heavily on the AHCPR practice guidelines for treating depression in primary care.